Mariner Wealth Advisors (NYC)’s Alexion Pharmaceuticals ALXN Stock Holding History

Mariner Wealth Advisors (NYC)’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	$50K	Buy	+288	New	+$52.1K	0.02%	156

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Mariner Wealth Advisors (NYC)'s ALXN Position: Q1 2015 in Review

Mariner Wealth Advisors (NYC) opened a new position in Alexion Pharmaceuticals (ALXN) in Q1 2015: 288 shares worth $50K. The stake represents 0.02% of the portfolio and ranks #156 among its holdings.

566 funds tracked by Wall St. Rank hold ALXN as of Q1 2015.

Mariner Wealth Advisors (NYC) held 288 shares of Alexion Pharmaceuticals worth $50K as of Q1 2015.
Alexion Pharmaceuticals was a new Mariner Wealth Advisors (NYC) position in Q1 2015.
Alexion Pharmaceuticals made up 0.02% of Mariner Wealth Advisors (NYC)'s portfolio in Q1 2015, its #156 holding.
566 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2015.

Based on Mariner Wealth Advisors (NYC)'s 13F filing for Q1 2015, filed 14 May 2015.